Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 2
2005 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B.
Offner F, Krcmery V, Boogaerts M, Doyen C, Engelhard D, Ribaud P, Cordonnier C, de Pauw B, Durrant S, Marie JP, Moreau P, Guiot H, Samonis G, Sylvester R, Herbrecht R; EORTC Invasive Fungal Infections Group. Offner F, et al. Antimicrob Agents Chemother. 2004 Dec;48(12):4808-12. doi: 10.1128/AAC.48.12.4808-4812.2004. Antimicrob Agents Chemother. 2004. PMID: 15561860 Free PMC article. Clinical Trial.
An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis.
Oude Lashof AM, De Bock R, Herbrecht R, de Pauw BE, Krcmery V, Aoun M, Akova M, Cohen J, Siffnerová H, Egyed M, Ellis M, Marinus A, Sylvester R, Kullberg BJ; EORTC Invasive Fungal Infections Group. Oude Lashof AM, et al. Eur J Cancer. 2004 Jun;40(9):1314-9. doi: 10.1016/j.ejca.2004.03.003. Eur J Cancer. 2004. PMID: 15177489 Clinical Trial.
Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.
Patterson TF, Boucher HW, Herbrecht R, Denning DW, Lortholary O, Ribaud P, Rubin RH, Wingard JR, DePauw B, Schlamm HT, Troke P, Bennett JE; European Organization for Research and Treatment of Cancer (EORTC) Invasive Fungal Infections Group (IFIG); Pfizer Global Aspergillus Study Group. Patterson TF, et al. Clin Infect Dis. 2005 Nov 15;41(10):1448-52. doi: 10.1086/497126. Epub 2005 Oct 13. Clin Infect Dis. 2005. PMID: 16231256 Clinical Trial.